ANADROL-50
LOE Approachingoxymetholone
NDAORALTABLET
Approved
Jan 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANADROL-50 (oxymetholone) is an oral anabolic steroid approved in 1972 for treating certain anemias and muscle-wasting conditions. The drug works by stimulating erythropoiesis and protein synthesis to increase red blood cell production and lean body mass. It is primarily indicated for aplastic anemia and other select hematologic disorders.
LOE Approaching
With LOE approaching and competitive pressure at 30%, commercial teams should anticipate portfolio transition planning and reduced headcount allocation to this legacy asset.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANADROL-50 offers minimal career growth opportunities due to its LOE-approaching status and zero linked job openings. Roles on this product are primarily defensive and focused on managed decline, portfolio rationalization, and compliance maintenance.
Field Sales RepresentativeBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.